A Randomized Phase 1/2 Trial of Low Dose Anti-thymocyte Globulin (ATG) With Subsequent Adalimumab or Verapamil in New Onset Type 1 Diabetes
A Randomized Phase 1/2 Trial of Low Dose Anti-thymocyte Globulin (ATG) With Subsequent Adalimumab or Verapamil in New Onset Type 1 Diabetes
Recruiting · NCT07061574 · Registry updated 2026-09-02Clinical trials
Swipe the table sideways for more columns.
| Trial | Conditions | Status | Phase | Updated | More info | NCT ID |
|---|---|---|---|---|---|---|
| A Randomized Phase 1/2 Trial of Low Dose Anti-thymocyte Globulin (ATG) With Subsequent Adalimumab or Verapamil in New Onset Type 1 Diabetes | Nutritional and Metabolic Diseases, autoimmune disease, diabetes mellitus, endocrine system disorder, glucose metabolism disease, immune system disorder, metabolic disease, type 1 diabetes mellitus | Recruiting | Phase 1 / Phase 2 | 2026-09-02 | NCT07061574 |
2 results · Page 1 of 1
Organizations
Swipe the table sideways for more columns.
| Organizations | Linked trials |
|---|---|
| City of Hope Medical Center | 347 |
| Jaeb Center for Health Research | 37 |
10 results · Page 1 of 1
Research sites
Swipe the table sideways for more columns.
| Research sites | City | Country | Linked trials |
|---|---|---|---|
| Baylor College of Medicine | Houston | United States | 306 |
| Indiana University | Indianapolis | United States | 160 |
| Seattle Children's Hospital | Seattle | United States | 281 |
| UCSF | San Francisco | United States | 27 |
| University of Buffalo | Buffalo | United States | 15 |
| University of Florida | Gainesville | United States | 144 |
| University of Miami | Miami | United States | 327 |
| University of Minnesota | Minneapolis | United States | 325 |
| University of Pittsburgh | Pittsburgh | United States | 9 |
| Yale University | New Haven | United States | 44 |